Enforcement Report - Week of December 26, 2013

Your browser settings indicate that JavaScript is currently disabled. Some features on this page may require the use of JavaScript. You may need to enable JavaScript in order to enjoy the full functionality of this page.

Marketed Without An Approved NDA/ANDA: FDA analysis detected the presence of sibutramine, N-Desmethylsibutramine and phenolphthalein. Sibutramine and phenolphthalein were previously available drug products but were removed from the U.S. market making these products unapproved new drugs.